Ventyx Biosciences (VTYX) Expected to Announce Earnings on Tuesday

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) is expected to issue its quarterly earnings data before the market opens on Tuesday, February 25th. Analysts expect Ventyx Biosciences to post earnings of ($0.54) per share for the quarter.

Ventyx Biosciences Trading Down 0.3 %

VTYX traded down $0.01 during trading hours on Friday, hitting $1.66. The company's stock had a trading volume of 164,827 shares, compared to its average volume of 1,612,575. Ventyx Biosciences has a fifty-two week low of $1.57 and a fifty-two week high of $11.48. The company has a 50-day simple moving average of $2.06 and a 200 day simple moving average of $2.16. The firm has a market capitalization of $117.03 million, a PE ratio of -0.70 and a beta of 0.52.

Insider Buying and Selling at Ventyx Biosciences

In related news, Director Sheila Gujrathi purchased 130,000 shares of the company's stock in a transaction that occurred on Monday, December 23rd. The shares were purchased at an average price of $2.31 per share, with a total value of $300,300.00. Following the purchase, the director now owns 130,000 shares of the company's stock, valued at $300,300. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider John Nuss sold 13,161 shares of the company's stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $2.26, for a total transaction of $29,743.86. Following the sale, the insider now directly owns 485,701 shares of the company's stock, valued at $1,097,684.26. This represents a 2.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 18.18% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on VTYX. HC Wainwright reaffirmed a "neutral" rating on shares of Ventyx Biosciences in a report on Tuesday, January 14th. Oppenheimer reiterated an "outperform" rating and set a $9.00 price objective (down previously from $10.00) on shares of Ventyx Biosciences in a research note on Friday, November 8th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Ventyx Biosciences currently has a consensus rating of "Moderate Buy" and an average price target of $10.00.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.